why choose us

First received: August 29, 2022

Clinical Trial: Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Endometrial Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)

Brief Summary: The purpose of this research study is to test the proportion of tumor response to the combination treatment with niraparib and bevacizumab and see what effects (good and bad) this combination treatment has on patients with recurrent endometrial or ovarian cancer with ARID1A mutation.

Read more